AU2018265888A1 - Use of anti-B7H3 antibodies for treating cancer in the central nervous system - Google Patents

Use of anti-B7H3 antibodies for treating cancer in the central nervous system Download PDF

Info

Publication number
AU2018265888A1
AU2018265888A1 AU2018265888A AU2018265888A AU2018265888A1 AU 2018265888 A1 AU2018265888 A1 AU 2018265888A1 AU 2018265888 A AU2018265888 A AU 2018265888A AU 2018265888 A AU2018265888 A AU 2018265888A AU 2018265888 A1 AU2018265888 A1 AU 2018265888A1
Authority
AU
Australia
Prior art keywords
antibodies
nervous system
central nervous
treating cancer
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018265888A
Other languages
English (en)
Inventor
Ole Baadsgaard
Kim KRAMER
Claus J. MØLLER SAN-PEDRO
Cheung NAI-KONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2018265888A1 publication Critical patent/AU2018265888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
AU2018265888A 2017-05-12 2018-05-14 Use of anti-B7H3 antibodies for treating cancer in the central nervous system Abandoned AU2018265888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505558P 2017-05-12 2017-05-12
US62/505,558 2017-05-12
PCT/US2018/032559 WO2018209346A1 (en) 2017-05-12 2018-05-14 Use of anti-b7h3 antibodies for treating cancer in the central nervous system

Publications (1)

Publication Number Publication Date
AU2018265888A1 true AU2018265888A1 (en) 2019-11-21

Family

ID=64102794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018265888A Abandoned AU2018265888A1 (en) 2017-05-12 2018-05-14 Use of anti-B7H3 antibodies for treating cancer in the central nervous system

Country Status (11)

Country Link
US (2) US20200197546A1 (https=)
EP (1) EP3635012A4 (https=)
JP (2) JP2020520382A (https=)
KR (1) KR20200008580A (https=)
CN (1) CN110799542A (https=)
AU (1) AU2018265888A1 (https=)
BR (1) BR112019023776A2 (https=)
CA (1) CA3062335A1 (https=)
EA (1) EA201992683A1 (https=)
RU (1) RU2019140833A (https=)
WO (1) WO2018209346A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185897A1 (en) * 2019-03-11 2020-09-17 Biocompatibles Uk Limited Radioactive microshperes for the treatment of cns tumours
WO2021037319A1 (en) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN117024591A (zh) * 2020-04-22 2023-11-10 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
US20230293738A1 (en) * 2020-04-24 2023-09-21 Y-Mabs Therapeutics, Inc. B7H3 Antibodies with Chelators
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
WO2022167052A1 (en) * 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
CN116867805A (zh) * 2021-09-27 2023-10-10 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN119744270A (zh) * 2022-07-08 2025-04-01 盛禾(中国)生物制药有限公司 一种异源二聚体融合蛋白及其应用
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
US9963509B2 (en) * 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof

Also Published As

Publication number Publication date
US20240415990A1 (en) 2024-12-19
JP2020520382A (ja) 2020-07-09
EP3635012A1 (en) 2020-04-15
EP3635012A4 (en) 2020-12-30
EA201992683A1 (ru) 2020-04-23
RU2019140833A3 (https=) 2022-02-07
BR112019023776A2 (pt) 2020-07-28
JP2023016969A (ja) 2023-02-02
KR20200008580A (ko) 2020-01-28
CA3062335A1 (en) 2018-11-15
CN110799542A (zh) 2020-02-14
US20200197546A1 (en) 2020-06-25
RU2019140833A (ru) 2021-06-15
WO2018209346A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
ZA202501583B (en) Compounds and methods for the targeted degradation of androgen receptor
ZA201904652B (en) Combinations of cabozantinib and atezolizumab to treat cancer
MX2024013523A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019500369A1 (en) Anti-tim-3 antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EP4656246A3 (en) Combination therapies for the treatment of cancer
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MA39818A (fr) Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
MX2022004766A (es) Terapias combinadas con venetoclax e inhibidores de tim-3.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AU2018380132A8 (en) Tubulin inhibitors
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
WO2019027987A3 (en) COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICE COMPLEX MUTATIONS
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted